Advertisement

Topics

Study identifies risk factors for cardiotoxicity with relapsed multiple myeloma therapy

23:51 EDT 13 Jun 2019 | News-Medical.net

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in Journal of Clinical Oncology.

Original Article: Study identifies risk factors for cardiotoxicity with relapsed multiple myeloma therapy

NEXT ARTICLE

More From BioPortfolio on "Study identifies risk factors for cardiotoxicity with relapsed multiple myeloma therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...